11C-methionine(11C-methionine) - 在研适应症：室管膜瘤，横纹肌肉瘤，颅咽管瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式

增强剂

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

室管膜瘤横纹肌肉瘤颅咽管瘤

非在研适应症-

原研机构

St. Jude Children's Research Hospital, Inc.

在研机构

St. Jude Children's Research Hospital, Inc.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与 11C-methionine 相关的临床试验

EUCTR2020-000640-64-CZ

/ Not yet recruiting临床2期IIT

11C-METHIONIN IN DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH AGGRESSIVE GLIOBLASTOM SHOWING A TIME POST-OPERATING PROGRESS BEFORE INITIATING ADJUVANT ONCOLOGICAL TREATMENT - GlioMET

开始日期2020-05-26

申办/合作机构-

NCT05608395

/ Active, not recruiting临床2期IIT

11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)

Glioblastoma multiforme (GBM) is the most common primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e. radiotherapy, chemotherapy, or combination of both at te same time. If post-operative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is planned. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery, i.e. rapid early progression (REP). Radiotherapy planning is based on this MRI in all patients. However, a subset of patients with REP have a less favorable prognosis with this treatment management. The investigators therefore assume that these patients need a more thorough examination to form a precise radiotherapy plan. The project focuses on this group of patients with a less favorable prognosis (with a more aggressive disease). Patients who develop REP within approximately 6 weeks after surgery will have PET/CT (positron emission tomography in combination with computed tomography) examinations using the radiopharmaceutical 11C-methionine in addition to standard practice. PET is one of the most modern methods of molecular imaging, a non-invasive in vivo method that allows physicians to study processes in the human body using radiolabeled radiopharmaceuticals. 11C-methionine is an example of a radiolabeled (carbon 11) amino acid - a source of energy for tumor cells and a building material for new proteins. This radiopharmaceutical is commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. For patients who undergo this examination, the radiotherapy planning will be adjusted based on it. The purpose of clinical trial is to improve the prospects of patients with REP.

开始日期2020-05-01

申办/合作机构

Masaryk Memorial Cancer Institute

JPRN-UMIN000037036

/ RecruitingN/AIIT

Study to investigate growth style of brain tumor using 11C-methionine PET - Study to investigate growth style of brain tumor using 11C-methionine PET

开始日期2019-06-12

申办/合作机构-

100 项与 11C-methionine 相关的临床结果

登录后查看更多信息

100 项与 11C-methionine 相关的转化医学

登录后查看更多信息

100 项与 11C-methionine 相关的专利（医药）

登录后查看更多信息

33

项与 11C-methionine 相关的文献（医药）

2024-06-01·Cancer Biotherapy and Radiopharmaceuticals

Evaluating the Diagnostic Efficacy of ^99mTc-Methionine Single-Photon Emission Computed Tomography–Computed Tomography: A Head-to-Head Comparison with ¹¹C-Methionine Positron Emission Tomography–Magnetic Resonance Imaging in Glioma Patients

Article

作者: Mangalore, Sandhya ; Basavaraja, Harish ; Rajan, Archith ; Sadashiva, Nishanth ; Mishra, Anil Kumar ; Hazari, Puja Panwar ; Saini, Jitender ; Kumar, Pardeep ; Nagaraj, Chandana ; Beniwal, Manish ; Santosh, Vani ; Kumar, Aishwarya ; Sitani, Keerti

Background: Amino acid positron emission tomography (PET) imaging plays a significant role in the diagnosis of gliomas and in differentiating tumor recurrence from necrosis. In this study, the authors evaluated the diagnostic efficacy of [^99mTc]Tc-methionine single-photon emission computed tomography-computed tomography (SPECT-CT) in comparison with [¹¹C]methionine PET-magnetic resonance imaging (MRI) in delineating tumors. Methods: Thirty-one (primary: 16 and postoperative: 15) patients of confirmed (either MRI or histopathological proven) glioma underwent both [^99mTc]Tc-methionine SPECT-CT and [¹¹C]methionine PET-MRI. A comparative analysis was performed between SPECT, PET, and MR images to calculate the concordance between the modalities and to evaluate the diagnostic efficacy of the [^99mTc]Tc-methionine SPECT. Results: [^99mTc]Tc-methionine SPECT showed comparable uptake in the tumor lesions in comparison to [¹¹C]methionine PET. A significant and strong positive correlation was observed between the volume of tumor (Vt) in PET and Vt MR (p < 0.004). Likewise, a significant and strong positive correlation was found between Vt SPECT and Vt MR. [^99mTc]-methionine has a sensitivity and specificity of 91% and 75%, respectively, compared with 82% and 100% for [¹¹C]methionine in postoperative cases to differentiate the tumor recurrence from necrosis. The sensitivity and specificity of [^99mTc]Tc-methionine was 92% and 100%, respectively, compared with 92% and 67% for [¹¹C]methionine in primary tumors. Conclusion: [^99mTc]Tc-methionine SPECT-CT is as equally good as [¹¹C]methionine for diagnosing and differentiating it from necrosis especially in high-grade glioma.

2023-08-01·Journal of neuro-oncology

T2-FLAIR mismatch sign correlates with ¹¹C-methionine uptake in lower-grade diffuse gliomas.

Article

作者: Tamura, Kaoru ; Ishii, Kenji ; Maehara, Taketoshi ; Nariai, Tadashi ; Hara, Shoko ; Tanaka, Yoji ; Ebiko, Yusuke ; Inaji, Motoki

PURPOSEThe T2-FLAIR mismatch sign is recognized as an imaging finding highly suggestive of IDH-mutant astrocytomas. This study was designed to determine whether the T2-FLAIR mismatch sign correlates with uptake of ¹¹C-methionine in lower-grade gliomas.METHODSWe included 78 histopathologically verified lower-grade gliomas (grade 2: 31 cases, grade 3: 47 cases) in this study. 78 patients underwent ¹¹C-methionine positron emission tomography (MET-PET) scans and magnetic resonance (MR) imaging scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of ¹¹C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. MR imaging scans were evaluated for the presence of the T2-FLAIR mismatch sign by three independent reviewers. We compared molecular status, the T2-FLAIR mismatch sign and ¹¹C-methionine uptake among patients with different lower-grade glioma molecular types.RESULTSThe 78 lower-grade gliomas were assigned to one of three molecular groups: Group A (IDH-mutant and 1p/19q non-codeleted, n = 22), Group O (IDH-mutant and 1p/19q codeleted, n = 20), and Group W (IDH wildtype, n = 36). T2-FLAIR mismatch was found in 16 cases (20.5%) that were comprised of 8 (36.4%), 0 (0%), 8 (22.2%) cases in the molecular group A, O and W, respectively. The median T/N ratio of MET-PET in tumors with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.83, p < 0.001, Mann-Whitney U test). In the Groups A and W (excluding Group O), the median T/N ratio on MET-PET in groups A and W (but not group O) with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.81, p = 0.002, Mann-Whitney U test).CONCLUSIONThe T2-FLAIR mismatch sign correlated with lower ¹¹C-methionine uptake in lower grade gliomas.

2023-06-01·EJNMMI physics

Development of a bespoke phantom to optimize molecular PET imaging of pituitary tumors.

Article

作者: Bird, Nick ; Mendichovszky, Iosif A ; Marsden, Daniel ; Aloj, Luigi ; Heard, Sarah ; Cheow, Heok ; Harper, Ines ; MacFarlane, James ; Ballout, Safia ; Santarius, Thomas ; Kolias, Angelos ; Crawford, Rosy ; Gillett, Bethany ; Bashari, Waiel ; Gurnell, Mark ; Mannion, Richard ; van der Meulen, Merel ; Koulouri, Olympia ; Powlson, Andrew S ; Gillett, Daniel

BACKGROUNDImage optimization is a key step in clinical nuclear medicine, and phantoms play an essential role in this process. However, most phantoms do not accurately reflect the complexity of human anatomy, and this presents a particular challenge when imaging endocrine glands to detect small (often subcentimeter) tumors. To address this, we developed a novel phantom for optimization of positron emission tomography (PET) imaging of the human pituitary gland. Using radioactive 3D printing, phantoms were created which mimicked the distribution of ¹¹C-methionine in normal pituitary tissue and in a small tumor embedded in the gland (i.e., with no inactive boundary, thereby reproducing the in vivo situation). In addition, an anatomical phantom, replicating key surrounding structures [based on computed tomography (CT) images from an actual patient], was created using material extrusion 3D printing with specialized filaments that approximated the attenuation properties of bone and soft tissue.RESULTSThe phantom enabled us to replicate pituitary glands harboring tumors of varying sizes (2, 4 and 6 mm diameters) and differing radioactive concentrations (2 ×, 5 × and 8 × the normal gland). The anatomical phantom successfully approximated the attenuation properties of surrounding bone and soft tissue. Two iterative reconstruction algorithms [ordered subset expectation maximization (OSEM); Bayesian penalized likelihood (BPL)] with a range of reconstruction parameters (e.g., 3, 5, 7 and 9 OSEM iterations with 24 subsets; BPL regularization parameter (β) from 50 to 1000) were tested. Images were analyzed quantitatively and qualitatively by eight expert readers. Quantitatively, signal was the highest using BPL with β = 50; noise was the lowest using BPL with β = 1000; contrast was the highest using BPL with β = 100. The qualitative review found that accuracy and confidence were the highest when using BPL with β = 400.CONCLUSIONSThe development of a bespoke phantom has allowed the identification of optimal parameters for molecular pituitary imaging: BPL reconstruction with TOF, PSF correction and a β value of 400; in addition, for small (< 4 mm) tumors with low contrast (2:1 or 5:1), sensitivity may be improved using a β value of 100. Together, these findings should increase tumor detection and confidence in reporting scans.

100 项与 11C-methionine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
室管膜瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2014-05-07
横纹肌肉瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2013-12-04
颅咽管瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2011-08-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2022	N/A	胶质瘤	21	[99mTc] methionine	(鹽網製醖壓築壓鬱鬱糧) = 網廠蓋鹹鑰願衊築壓淵憲遞壓壓壓蓋範夢範繭 (襯淵鑰蓋願餘蓋積壓壓 ) 更多	-	2022-09-22
				[11C] methionine	(鹽網製醖壓築壓鬱鬱糧) = 製網壓鏇繭繭獵膚襯艱憲遞壓壓壓蓋範夢範繭 (襯淵鑰蓋願餘蓋積壓壓 ) 更多
SNMMI2022	N/A	多发性骨髓瘤	-	11C-Methionine (MM patients)	(選蓋簾壓壓鬱鑰繭膚窪) = 衊憲鹹獵壓構糧膚憲艱襯蓋範襯範繭夢夢蓋網 (餘顧製餘鹽蓋襯鏇鑰獵, 6.6)	-	2022-08-08
				11C-Methionine (Controls)	(選蓋簾壓壓鬱鑰繭膚窪) = 遞憲夢衊網遞淵窪鹹繭襯蓋範襯範繭夢夢蓋網 (餘顧製餘鹽蓋襯鏇鑰獵, 0.8)
EANM2021	N/A	胶质瘤 IDH-mutant \| IDH-wildtype	201	11 C-methionine (PET-positive patients)	(築蓋網衊鏇網壓壓鹽淵) = 網蓋艱獵顧鏇顧蓋鹹壓衊廠蓋襯鹽網選襯夢鑰 (壓觸鑰餘鬱壓鏇淵齋艱 )	-	2021-09-24
				11 C-methionine (PET-negative patients)	(築蓋網衊鏇網壓壓鹽淵) = 選夢鑰膚築鹹蓋壓鹽遞衊廠蓋襯鹽網選襯夢鑰 (壓觸鑰餘鬱壓鏇淵齋艱 )
EANM2020	N/A	可见病灶 11C-Methionine \| perfusion weighted imaging (PWI)	10	11C-Methionine (Perfusion Weighted Imaging (PWI))	淵築觸憲製鏇製醖淵願(積齋築願餘淵襯願廠鑰) = mean DICE index between PET and Gd-VOIs of the lesions was moderate (0.58 ± 0.15) 簾憲艱積淵簾鏇廠獵範 (壓襯廠鑰構築顧醖窪鏇 ) 更多	-	2020-09-18
ASTRO2019	N/A	胶质母细胞瘤	-	(11)C-Methionine (11C-methionine (MET)-PET)	憲蓋獵簾憲構夢願窪膚(鏇鹽構廠繭顧構遞構夢) = 憲餘築醖觸鬱窪窪廠製淵獵鹹觸構製壓範製選 (選鬱淵糧鹽壓顧夢繭願, 0 ~ 43.8)	-	2019-09-01
SNMMI2018	N/A	辐射损伤 \| 脑癌	-	11C-methionine (Brain Tumor Recurrence)	淵廠鹽膚簾願衊範齋築(糧艱範襯選築衊夢襯廠) = 糧顧鑰膚鹹餘壓獵選製繭糧積襯窪鑰遞壓餘鑰 (膚築糧選醖遞觸壓憲淵, 0.15)	-	2018-05-23
				11C-methionine (Radiation Necrosis)	淵廠鹽膚簾願衊範齋築(糧艱範襯選築衊夢襯廠) = 壓膚醖蓋鑰製餘鏇齋遞繭糧積襯窪鑰遞壓餘鑰 (膚築糧選醖遞觸壓憲淵, 0.22)
11 C-Methionine PET Examination (SNMMI2018)	N/A	胶质瘤 isocitrate dehydrogenase 1-R132H mutational status (IDH1-R132H)	160	11 C-Methionine (Male patients)	構夢淵淵鏇淵夢衊壓窪(鏇憲顧觸糧餘獵膚鏇衊) = 艱遞鑰構簾網積餘獵顧繭壓鬱獵積蓋鹽顧願製 (製衊醖齋顧淵膚獵築構 )	-	2018-05-23
				11 C-Methionine (Female patients)	構夢淵淵鏇淵夢衊壓窪(鏇憲顧觸糧餘獵膚鏇衊) = 鬱艱壓憲鏇積鬱願壓鏇繭壓鬱獵積蓋鹽顧願製 (製衊醖齋顧淵膚獵築構 )
EANM2016	N/A	多发性骨髓瘤	26	11C-Methionine18FDGethionine (18FDG PET/CT)	憲築餘鬱鑰齋獵鹽鏇觸(選壓繭繭膚築醖範積蓋) = 遞齋淵築淵衊蓋願齋簾憲製選襯膚構製願糧範 (糧獵鏇遞願範廠夢糧艱 )	积极	2016-09-21
SNMMI2016	N/A	心肌梗塞	-	11C-methionine (Coronary artery ligation)	憲齋襯窪鬱夢窪願膚鹹(鏇網齋鏇築鏇膚構範築) = 範蓋顧鹹艱蓋願範窪艱鑰鏇蓋繭鏇鏇願範淵構 (淵齋遞醖積窪鹹鑰鬱艱, 0.9)	-	2016-05-24
				11C-methionine (No surgery)	憲齋襯窪鬱夢窪願膚鹹(鏇網齋鏇築鏇膚構範築) = 夢餘憲憲鬱窪鏇積壓獵鑰鏇蓋繭鏇鏇願範淵構 (淵齋遞醖積窪鹹鑰鬱艱, 0.5)
SNMMI2016	N/A	肿瘤 11C-methionine	45	11C-methionine (Convolutional neural network (CNN))	餘簾構淵獵廠夢網簾蓋(艱憲觸襯顧鏇網醖築範) = 醖蓋製鏇齋鏇鏇蓋積鹹醖窪衊艱齋蓋餘憲醖顧 (醖積製蓋壓鏇艱鬱廠夢, 5.5) 更多	积极	2016-05-24
				11C-methionine (SUVmax measurement)	餘簾構淵獵廠夢網簾蓋(艱憲觸襯顧鏇網醖築範) = 選範醖顧鹽艱觸艱衊繭醖窪衊艱齋蓋餘憲醖顧 (醖積製蓋壓鏇艱鬱廠夢 ) 更多